• Ganesh, A.N.; Aman, A.; Logie, J.; Barthel, B.L.; Cogan, P.; Al-awar, R.; Koch, T.H.; Shoichet, B.K.; Shoichdet, M.S,; Colloidal Drug Aggregate Stability in High Serum Conditions and Pharmacokinetic Consequences, ACS Chem. Biol. 2019, 14, 751-757.
  • Tamura, R.; Balabanova, A.; Frakes, S.A.; Bargmann, A.; Grimm, J.; Koch, T.H.; Yin, H. J.; Photoactivatable Prodrug of Doxazolidine Targeting Exosomes, J. Med. Chem. 2019, 62, 1959—1970.
  • Barthel, B. L.; Mooz, E. L.; Wiener, L. E.; Koch, G. G.; Koch, T. H. Correlation of in Situ Oxazolidine
    Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from
    Combinations of Doxorubicin and Formaldehyde. J. Med. Chem., 2016, 59, 2205-2221.
  • Barthel, B.L.; Rudnicki, D.L.; Kirby, T.P.; Colvin, S.M.; Burkhart, D.J.; Koch, T.H.; Synthesis and Biological Characterization of Protease-Activated Prodrugs of Doxazolidine, J. Med. Chem., 2012, 55, 6595-6607.
  • Gold, L.; Ayers, D.; Bertino, J.; Bock, C.; Bock, A.; Brody, E.N.; Carter, J.; Dalby, A.; Eaton, B.E.; Fitzwater, T.; Flather, D.; Forbes, A.; Foreman, T.; Fowler, C.; Gawande, B.; Goss, M.; Gunn, M.; Gupta, S.; Halladay, D.; Heil, J.; Heilig, J.; Hicke, B.; Husar, G.; Janjic, N.; Jarvis, T.; Jennings, S.; Katilius, E.; Keeney, T.R.; Kim, N.; Koch, T.H.; Kraemer, S.; Kroiss, L.; Le, N.; Levine, D.; Lindsey, W.; Lollo, B.; Mayfield, W.; Mehan, M.; Mehler, R.; Nelson, S.K.; Nelson, M.; Nieuwlandt, D.; Nikradi, M.; Ochsner, U.; Ostroff, R.M.; Otis, M.; Perker, T.; Pietrasiewicz, S.; Schneider, D.; Singer, B.; Stanton, M.; Sterkel, A.; Stewart, A.; Stratford, S.; Vaught, J.D.; Vrkljan, M.; Walker, J.J.; Watrobka, M.; Waugh, S.; Weiss, A.; Wilcox, S.; Wolfson, A.; Wolk, S.; Zhang, C.; Zichi, D. “Aptamer-based multiplexed proteomic technology for biomarker discovery”, PLoS ONE 5(12) 2010: e15004. doi:10.1371/journal.pone.0015004.
  • Barthel, B.L.; Zhang, Z.; Rudnicki, D.L.; Coldren, C.D.; Polinkovsky, M.; Sun, H.; Koch, G.G.; Chan, D.C.F.; Koch, T.H. "Preclinical Efficacy of a Carboxylesterase 2-Activated Prodrug of Doxazolidine", J. Med. Chem. 2009, 52, 7678-7688.
  • Koch, T.H.; Barthel, B.L.; Kalet, B.T.; Rudnicki, D.L.; Post, G.C.; Burkhart, D.J. "Anthracycline-formaldehyde Conjugates and Their Targeted Prodrugs", Topics in Current Chemistry, 2008, 283, 141-170.
  • Spencer, D.M.; Bilardi, R.A.; Koch, T.H.; Post, G.C.; Nafie, J.W.; Kimura, K.-I.; Cutts, S..; Phillips, D.R. "DNA Repair in Response to Anthracycline-DNA Adducts: A Role for both Homologous Recombination and Nucleotide Excision Repair", Mutation Res. 2008, 638, 110-121.
  • Barthel, B.L.; Torres, R.C.; Hyatt, J.L.; Edwards, C.C.; Hatfield, M.J.; Potter, P.M.; Koch, T.H. "Identification of Human Intestinal Carboxylesterase as the Primary Enzyme for Activation of a Doxazolidine Carbamate Prodrug", J. Med. Chem. 2008, 51, 298-304.
  • Kalet, B.T.; McBryde, M.B.; Espinosa, J.M.; Koch, T.H. "Doxazolidine Induction of Apoptosis by a Topoisomerase II Independent Mechanism", J. Med. Chem. 2007, 50, 4493-4500.
  • Burkhart, D.J.; Barthel, B.L.; Post, G.C.; Kalet, B.T.; Nafie, J.W.; Shoemaker, R.K.; Koch, T.H. "Design, Synthesis, and Preliminary Evaluation of Doxazolidine Carbamates as Prodrugs Activated by Carboxylesterases", J. Med. Chem. 2006, 49, 7002-7012.
  • Post, G.C.; Barthel, B.L.; Burkhart, D.J.; Hagadorn, J.R.; Koch, T.H. "Doxazolidine, a Proposed Active Metabolite of Doxorubicin That Cross-links DNA", J. Med. Chem. 2005, 48, 7648-7657.
  • Burkhart, D.J.; Kalet, B.T.; Coleman, M.P.; Post, G.C.; Koch, T.H. "Doxorubicin-formaldehyde Conjugate Targeting µvb3 Integrin", Mol. Cancer Therap. 2004, 3, 1593-1604.
  • Burke, P.J.; Kalet, B.T.; Koch, T.H. "Antiestrogen Binding Site (AEBS) and Estrogen Receptor (ER) Mediate Uptake and Distribution of 4-Hydroxytamoxifen-targeted Doxorubicin-formaldehyde Conjugate in Breast Cancer Cells" J. Med. Chem. 2004, 47, 6509-6518.
  • Cogan, P.S.; Koch, T.H. "Studies of Targeting and Intracellular Trafficking of an Anti-Androgen-Doxorubicin-Formaldehyde Conjugate in PC-3 Prostate Cancer Cells Bearing Androgen Receptor-GFP Chimera", J. Med. Chem. 2004, 47, 5690-5699.
  • Cogan, P.S.; Fowler, C.R.; Post, G.C.; Koch, T.H. "Doxsaliform: A novel N-Mannich base prodrug of a doxorubicin-formaldehyde conjugate", Lett. Drug Design Dis., 2004, 1, 247-255.
  • Burke, P.J.; Koch, T.H. "Design, Synthesis, and Biological Evaluation of Doxorubicin-Formaldehyde Conjugates Targeted to Breast Cancer Cells" J. Med. Chem. 2004, 47, 1193-1206.
  • Koch, T.H.; Smith, D.; Tabacman, E.; Zichi, D. A. "Kinetic Analysis of Site-specific Photoaptamer-Protein Cross-Linking" J. Mol. Biol. 2004, 336, 1159-1173.
  • Cogan, P.S.; Koch, T.H. "Rational Design and Synthesis of Androgen Receptor Targeted Non-Steroidal Anti-Androgen Ligands for the Tumor Specific Delivery of a Doxorubicin-Formaldehyde Conjugate", J. Med. Chem.2003, 46, 5258-5270.
  • Smith, D.; Collins, B. D.; Heil, James, Koch, T. H. "Sensitivity and Specificity of Photoaptamer Probes" Mol. Cell. Proteomics, 2003, 2.1, 11-18.
  • Golden, M. C.; Collins, B. D.; Willis, M. C.; Koch, T. H. "Selection of Highly Specific and Sensitive ssDNA Photocross-Linking Aptamers to Target Proteins Using PhotoSELEX and Their Diagnostic Potential", in Gene Cloning and Expression Technologies (Weiner, M. P.; Lu, Q., eds), Eaton Publishing, Westborough, MA, 2002, pp 477-491.
  • Kato, S.; Post, G. C.; Bierbaum, V. M.; Koch, T. H. "Chemical Ionization Mass Spectrometric Determination of Acrolein in Human Breast Cancer Cells", Anal. Biochem., 2002, 305, 251-259.
  • Dernell, W. S.; Powers, B. E.; Taatjes, D. J.; Cogan, P.; Gaudiano, G.; Koch, T. H. "Evaluation of the Epidoxorubicin-formaldehyde Conjugate, Epidoxoform, in a Mouse Mammary Carcinoma Model" Cancer Invest., 2002, 20, 713-724.
  • Kato, S.; Burke, P. J.; Koch, T.; Bierbaum, V. M. "Formaldehyde in Human Cancer Cells: Sensitive Detection by Distillation Sampling-Chemical Inoization Mass Spectrometry and Prognostic Implications" Anal. Chem., 2001, 73, 2992-2997.
  • Burke, P. J.; Koch, T. H. "Doxorubicin-formaldehyde Conjugate, Doxoform: Induction of Apoptosis Relative to Doxorubicin" Anticancer Res., 2001, 21:4A, 2753-2760.
  • Kato, S.; Burke, P. J.; Fenick, D. J.; Taatjes, D. J.; Bierbaum, V. M.; Koch, T. H. "Mass Spectrometric Measurement of Formaldehyde Generated in Breast Cancer Cells upon Treatment with Anthracycline Antitumor Drugs" Chem. Res. Toxicol., 2000, 13, 509-516.
  • Taatjes, D. J.; Koch, T. H. "Nuclear Targeting and Retention of Anthracycline Antitumor Drugs in Sensitive and Resistant Tumor Cells", Current Med. Chem., 2001, 8, 15-29.
  • Golden, M. C.; Collins, B. D.; Willis, M. C.; Koch, T. H. "Diagnostic Potential of PhotoSELEX-Evolved ssDNA Aptamers", J. Biotechnol., 2000, 81, 167-178.
  • Gaudiano, G.; Koch, T. H.; Lo Bello, M.; Nuccetelli, M.; Ravagnan, G.; Serafino, A.; Sinibaldi-Vallebona, P. "Lack of Glutathione Conjugation to Adriamycin in Human Breast Cancer MCF-7/DOX Cells", Biochem. Pharm., 2000, 60, 1915-1923.
  • Podell, E. R.; Harrington, D. J.; Taatjes, D. J.; Koch, T. H. "Crystal Structure of Epidoxorubicin-formaldehyde Virtual Crosslink of DNA and Evidence for Its Formation in Human Breast Cancer Cells", Acta Cryst. D, 1999, D55, 1516-1523.
  • Meisenheimer, K. M.; Meisenheimer, P. L.; Koch, T. H. "Nucleoprotein Photocrosslinking Using Halopyrimidine-Substituted RNAs", Methods in Enzymol., 2000, 318, 88-104.